Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BIG MONEY KNOWS CHARLES, JOSEPH, AND HARRY VERY VERY WELL! #GAMECHANGER
$ENZC Private Equity Manager with interest in @BioClonetics https://t.co/QszGQ3aT1b
YOU HAVE NO CLUE IN THE WORLD THE TIES THESE GUYS HAVE. U WILL FIND OUT SOON ENOUGH. DDDDDDDD
There is a Very Big Story to Tell once our Merger is Completed. My bet, This Month at Anytime.
Will see .10 in short order, Big Connections if you do your DD. Good day.
Monoclonal antibodies are one of the potential coronavirus treatments that scientists are “really quite optimistic about,” Fauci said.
This is CRAZY. Who knows, but damn... https://news.zoetis.com/press-releases/press-release-details/2018/Regeneron-and-Zoetis-Announce-Collaboration-to-Research-Antibody-Therapies-for-Use-in-Animal-Health/default.aspx ALL ABOUT WHO KNOWS WHO, CONNECTIONS!
Remember my post:
Hello, my name is Rich Krebs. I'm currently a Senior Principal Scientist with Zoetis. We are an animal health company who recently introduced the first animal health monoclonal antibody treatment. I'm a believer in the concept and I believe your company is able to accomplish it's goals.
Richard Krebs
Senior Principal Scientist in R&D for an animal health company.
INVESTOR IN BioClonetics!!!
Look up Zoetis!!
Zoetis Inc. is the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. Wikipedia
Stock price: ZTS (NYSE) $160.87 +0.40 (+0.25%), now 163 per share!
Sep 18, 4:05 PM EDT - Disclaimer THIS GUY INVESTED IN BIOCLONETICS FOLKS! U THINK THIS COMPANY KNOWS WHO BIOCLONETICS IS NOW??!!! LOL! I DO!
Thank You! DD never stops, Always a nugget, a tie, a CONNECTION To Find.
$ENZC Once Again, A GREAT READ From Last year. PAY ATTENTION! https://t.co/Ox3U9jqvKx Most importantly, we are also NOW WORKING CLOSELY with SCRIPPS Institute where our Recombinant Antibodies will be additionally tested in several test systems to further validate their efficacy.
— Cheers (@crabbermike) October 5, 2020
$ENZC Y would a Company B Excited About attacking #Covid19? THEY KNOW WHAT THEY HAVE! Great read here: https://t.co/5oTzrgiboT WHO DID I MENTION 2DAY THAT IS WORKING WITH @BioClonetics? @scrippsresearch HIV research has paved the way in terms of technology dev at Scripps Research
— Cheers (@crabbermike) October 5, 2020
Shawn Leon 6:57 PM
Hi Michael,
The shareholder is very reputable and has invested over 2 million into Ethema. Those numbers only represent what they would own if they converted all of their notes and exercised all of their warrants. They are not in the money on warrants and still have half of their notes.
we have to file Q2 and it is in process with the auditors. can never put a date on it as they never meet their projections.
Betting on Silver this year.
Much silver!!
MANY Large and SMALL Pharmas know who BioClonetics as well as Enzolytics are. I made calls, many. Enjoy the week folks, the Combined Technology is and will be a Gamechanger for the Industry.
Do Not let those precious shares go
$ENZC The time has Arrived for this Gem in the Making #HIV #COVID19 #CORONAVIRUS #GAMECHANGER $REGN $LLY $DNA $JNJ $AMGN $MRK $BIIB $GILD $EPZY $ZTS $LEGN $PASO $BYOC $AMRN $NWBO $CYDY $IBIO $LEAS $BRTXQ $GOVX $RNWF $MSFT $PFE $NKLA $GFTX $MRNA $LONE $TSLA $CLIG $NVAX $GSK $INO pic.twitter.com/sk1Fbj8iro
— Cheers (@crabbermike) October 4, 2020
$ENZC #INVESTORS READ https://t.co/kojNBishrh
— Cheers (@crabbermike) October 4, 2020
Thank you for your post. I can tell you, I have done hours upon hours of DD. I have posted a ton, but also have kept alot to myself as I keep adding shares to my stash.
I have dug throughout the Internet, sent emails, made many many phone calls to the Company, to Big Pharma, to Big stock holders, on and on. So much to find.
One thing always sticks out to me, and it came from Management, as they are NOW COMPLETING their milestones. I was told how very excited they are about the potential for COVID19 and HIV. BUT they have been saying this about Bioclonetics for a long time, and that it is nice to be acknowledged for the work they have put in. HMMMMM, ACKNOWLEDGED by WHOM? Tic Tok, hold those shares tight friends!
Here is some, I have found so much that Todays is enough to Convince ME, the time to truly fight HIV and Covid is upon us with this Merger of Enzolytics Inc and BioClonetics. PATENTS, Sector Connections and Ties, TONS Of EXPERIENCE, on and on!
BioClonetics said that because of the similar structures of HIV and COVID-19 and the efficacy of its Clone 3 antibody in fighting HIV, the company has been asked by the National Science Foundation @NSF to submit a funding application for development of a COVID-19 antibody. The company currently has applications pending with the NSF and the National Institutes of Health.
Remember, this was months ago. Betting they got PLENTY TO TELL IN THE NEAR TERM.
our Duke PHD https://surgery.duke.edu/news/david-montefiori-phd-receives-326-million-grant-gates-foundation-hiv-vaccine-research
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158370680
LET THIS SINK IN: BioClonetics FINAL stage of development of a parent monoclonal antibody ("mAbs") (designated as Clone 3), which is non-toxic & has shown in initial in vitro testing 2 B Effective against More than 95% of ALL Strains & viral subtypes of HIV-1 against which it's been tested
BioClonetics INVITED by the National Science Foundation (NSF) 2 submit an application 4 funding 4 development of anti-SARS-Cov-2 monoclonal antibodies using its proprietary #Technology. Such application to the NSF & a corresponding application to the NIH R NOW PENDING
The Company is also looking to expand its Medical Advisory board with individuals that have direct experience taking medical products through the regulatory process and bringing them to market. Betting we do NOT have to look far for these Additions.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158391702
Okay, Now some serious ties: Easier to post pages so I do not run out of room, lmao!
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158402294
More on Genscript: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158402747
https://www.linkedin.com/in/craigvomlehn/ Click Interest, Then Companies!!!
ALSO http://bioclonetics.com/who-we-are.html
Key Figure is Tomasz Zastawny, Chief Clinical Operations Officer, DSc, Ph.D.
Vice President, Head of Clinical Operations at Epizyme
https://www.linkedin.com/company/epizyme/about/ HUGE!!!
$EPZY NASDAQ $11
Hello, my name is Rich Krebs. I'm currently a Senior Principal Scientist with Zoetis. We are an animal health company who recently introduced the first animal health monoclonal antibody treatment. I'm a believer in the concept and I believe your company is able to accomplish it's goals.
Richard Krebs
Senior Principal Scientist in R&D for an animal health company.
INVESTOR IN BioClonetics!!!
Look up Zoetis!!
Zoetis Inc. is the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. Wikipedia
Stock price: ZTS (NYSE) $160.87 +0.40 (+0.25%), now 163 per share!
Sep 18, 4:05 PM EDT - Disclaimer THIS GUY INVESTED IN BIOCLONETICS FOLKS! U THINK THIS COMPANY KNOWS WHO BIOCLONETICS IS NOW??!!! LOL! I DO!
1 MORE BIGGIE DD and TIES.
THE BUZZ ABOUT BIOCLONETICS IMMUNOTHERAPEUTICS
Despite effective anti-HIV retrovirals, clearance of HIV-1 remains a critical global health issue. We are excited to be part of your strong interdisciplinary team and you have our full support for successful advancement of your technology.
Magdalena Leszczyniecka, Ph.D., MBA
CEO and Present, STC Biologics, Inc.
DD HER and Her Company!! Started at Novartis
Pharmaceuticals
https://stcbiologics.com/
STC was founded in 2009 and its team brings expertise in biologics drug development and global regulatory approvals from Genentech, Novartis, Shire, EMD Serono, Lonza, Alexion and Merrimack.
She gained start up experience prior to STC working for venture capital firms: Flagship Ventures and Atlas Ventures. She has led the development of MM-121 and anti-HER3 antibody programs at Merrimack Pharmaceuticals.
Here is more from her: https://www.rihl.in/hiv-curable-now-with-monoclonal-antibodies/
This is old, but once again, Shows People knowing People and Companies
Page 19 and 73
https://conshouston.esteri.it/resource/2011/11/42712_f_cons57RaccoltainterventiConferenzadeiRicercatori2010.pdf
Lastly, old but... you get the point!!
https://www.digitalnicheagency.com/ BUT...listed on the page with big names just looks nice as shit folks!!
CHEERS TO THIS MERGER!! GAMECHANGER!
EXACTLY! #COVID AND #HIV PLUS OTHER INFECTIOUS DISEASES. HUGE POTENTIAL
Do Not 4get this DD for ALL! I have found so much that Todays is enough to Convince ME, the time to truly fight HIV and Covid is upon us with this Merger of Enzolytics Inc and BioClonetics. PATENTS, Sector Connections and Ties, TONS Of EXPERIENCE, on and on!
BioClonetics said that because of the similar structures of HIV and COVID-19 and the efficacy of its Clone 3 antibody in fighting HIV, the company has been asked by the National Science Foundation @NSF to submit a funding application for development of a COVID-19 antibody. The company currently has applications pending with the NSF and the National Institutes of Health.
Remember, this was months ago. Betting they got PLENTY TO TELL IN THE NEAR TERM.
our Duke PHD https://surgery.duke.edu/news/david-montefiori-phd-receives-326-million-grant-gates-foundation-hiv-vaccine-research
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158370680
LET THIS SINK IN: BioClonetics FINAL stage of development of a parent monoclonal antibody ("mAbs") (designated as Clone 3), which is non-toxic & has shown in initial in vitro testing 2 B Effective against More than 95% of ALL Strains & viral subtypes of HIV-1 against which it's been tested
BioClonetics INVITED by the National Science Foundation (NSF) 2 submit an application 4 funding 4 development of anti-SARS-Cov-2 monoclonal antibodies using its proprietary #Technology. Such application to the NSF & a corresponding application to the NIH R NOW PENDING
The Company is also looking to expand its Medical Advisory board with individuals that have direct experience taking medical products through the regulatory process and bringing them to market. Betting we do NOT have to look far for these Additions.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158391702
Okay, Now some serious ties: Easier to post pages so I do not run out of room, lmao!
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158402294
More on Genscript: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158402747
https://www.linkedin.com/in/craigvomlehn/ Click Interest, Then Companies!!!
ALSO http://bioclonetics.com/who-we-are.html
Key Figure is Tomasz Zastawny, Chief Clinical Operations Officer, DSc, Ph.D.
Vice President, Head of Clinical Operations at Epizyme
https://www.linkedin.com/company/epizyme/about/ HUGE!!!
$EPZY NASDAQ $11
Hello, my name is Rich Krebs. I'm currently a Senior Principal Scientist with Zoetis. We are an animal health company who recently introduced the first animal health monoclonal antibody treatment. I'm a believer in the concept and I believe your company is able to accomplish it's goals.
Richard Krebs
Senior Principal Scientist in R&D for an animal health company.
INVESTOR IN BioClonetics!!!
Look up Zoetis!!
Zoetis Inc. is the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. Wikipedia
Stock price: ZTS (NYSE) $160.87 +0.40 (+0.25%), now 163 per share!
Sep 18, 4:05 PM EDT - Disclaimer THIS GUY INVESTED IN BIOCLONETICS FOLKS! U THINK THIS COMPANY KNOWS WHO BIOCLONETICS IS NOW??!!! LOL! I DO!
1 MORE BIGGIE DD and TIES.
THE BUZZ ABOUT BIOCLONETICS IMMUNOTHERAPEUTICS
Despite effective anti-HIV retrovirals, clearance of HIV-1 remains a critical global health issue. We are excited to be part of your strong interdisciplinary team and you have our full support for successful advancement of your technology.
Magdalena Leszczyniecka, Ph.D., MBA
CEO and Present, STC Biologics, Inc.
DD HER and Her Company!! Started at Novartis
Pharmaceuticals
https://stcbiologics.com/
STC was founded in 2009 and its team brings expertise in biologics drug development and global regulatory approvals from Genentech, Novartis, Shire, EMD Serono, Lonza, Alexion and Merrimack.
She gained start up experience prior to STC working for venture capital firms: Flagship Ventures and Atlas Ventures. She has led the development of MM-121 and anti-HER3 antibody programs at Merrimack Pharmaceuticals.
Here is more from her: https://www.rihl.in/hiv-curable-now-with-monoclonal-antibodies/
This is old, but once again, Shows People knowing People and Companies
Page 19 and 73
https://conshouston.esteri.it/resource/2011/11/42712_f_cons57RaccoltainterventiConferenzadeiRicercatori2010.pdf
Lastly, old but... you get the point!!
https://www.digitalnicheagency.com/ BUT...listed on the page with big names just looks nice as shit folks!!
CHEERS TO THIS MERGER!! GAMECHANGER!
Here is a good one!! $ENZC Monoclonal Antibodies Could Fill the COVID-19 Treatment Gap Until Vaccines Arrive — But at a Cost https://t.co/b63VLRo2Tr via @chronline "If they are successful, monoclonal antibodies are really going to revolutionize treatment for COVID-19," said Dr. Larry Corey
Especially: If they are successful, monoclonal antibodies are really going to revolutionize treatment for COVID-19," said Dr. Larry Corey HELL, NO NOT FORGET HIV FOLKS!
"Pharmaceutical companies are gearing up to begin manufacturing even before the final results are in."
And remember, BioClonetics already mentioned having pharmas ready in the past.
Uncle Billy Killing it Today!! Nice brother.
As is THIS!! Potential is mindblowing!
Also raises the question of whether he was on famotidine (Pepcid) for heartburn or are preventive/treatment for SARS-CoV-2. https://t.co/dnH09rufjV
— Jon Cohen (@sciencecohen) October 2, 2020
Boom! DO NOT LOSE YOUR SHARES FOLKS!! I TOLD U OCTOBER IS OUR MONTH!! JUST BEGINNING
$ENZC MONOCLONAL ANTIBODIES IS THE HOTTEST PART OF THE #BIOTECHNOLOGY SECTOR 2DAY & THIS FALL! @BioClonetics https://t.co/LlJYNGSfjy #GameChanger $AMRN $ABCE $JNJ $MRK $GLD $ELI $MARK $SHMP $OWCP $CYDY $TSLA $OPTI $RBII $SBES $GRNF $SPOM $PENN $DKNG $AMD $MSFT #TrumpHasCovid $BTC
— Cheers (@crabbermike) October 2, 2020
BUY BUY BUY THUS HIDDEN GEM
This one Will Explode North this month From Outside Ihub and Twitter Money. Count on it. Those that follow these boards and think they can buy at anytime will be soooo MISTAKEN.
All should be accumulating all they can. GLTU, later all
OCTOBER IS OUR MONTH!! Buy all you can so you have SIZE. BOOOM
Hottest Sector! UCSF University of California, San Francisco Testing New #COVID Treatment: UCSF researchers are testing a promising COVID-19 drug that could lessen symptoms and keep people out of the hospital. The drug, called a MONOCLONAL ANTIBODY
Monoclonal Antibody ("mAbs") (designated as Clone 3) #Covid19 "The worldwide case count passed 34 million Thursday morning, with more than 1 million reported deaths, according to Johns Hopkins University's COVID-19 dashboard."
Todays pr was CONFIRMATION THIS DEAL CLOSES! Then, we see additional Members added. Monster in the Making
$ENZC Monoclonal Antibodies, The Sector to B In! Enzolytics/BioClonetics Inc Will B HUGE! https://t.co/XNOaVXfHUC
— Cheers (@crabbermike) October 1, 2020
$REGN $MRK $FBIO $JNJ $GILD $LLY $PFE $NIO $NVAX $CVAC $MRNA $BNTX $ENLV $ABCE $SPOM $FPVD $TSLA $AAPL $AMD $DKNG $TTCM $OPTI $NSPX $AMRN $SPAQ $TPTW $PENN #STOCKS
$ENZC OCTOBER HAS ARRIVED BioClonetics Inc. is in the FINAL Stage of Development of a Parent Monoclonal Antibody (mAbs) (designated as Clone 3) #HIV #Covid19 "Development of anti-SARS-Cov-2 MONOCLONAL ANTIBODIES" $REGN $MRK $FBIO $JNJ $GILD $LLY $PFE $NIO $NVAX $CVAC $MRNA $BNTX pic.twitter.com/VinzLOj9Ag
— Cheers (@crabbermike) October 1, 2020
I like this: Eli Lilly indicates it plans to manufacture the antibodies in facilities in Kinsale, Ireland and New Jersey. It is also willing to work out manufacturing deals with other company’s antibody treatments if their own clinical trials fail.
Meanwhile, Lilly is continuing to search for antibodies via a partnership with AbCellera, which is working with the U.S. National Institutes of Health to identify promising compounds.
Ties/Connections/Ties/Connections
Got that right moolamoola and brezlin. now is the time to accumulate, it will be hard getting size once this Merger Closes.
Really? Fins, Merger, Advisory Board Members are NEAR TERM. I expect all to be done ANYTIME in October. Ties large Pharma, producer names could be announced. We have no clue what all they have going on. Gonna be big, very big, imho. GLTU regardless
This Sector is about ready to EXPLODE!! Sounds about right from an article I just Read Concerning Monoclonal Antibodies
"They are a real best chance of being a game changer,” according to Francis S. Collins, director of the National Institutes of Health.
Keep Adding Cheapies!
ADDED, SHHHHHHHHHH! OCTOBER WILL BE BIOCLONETCS AND ENZOLYTICS MONTH
If you only knew!! Bwahahaha! Make some Calls, send emails, make more calls to everyone they are tied to. Info is to be found. HUGE!!
Thanks. Hit me on twitter, crabbermike. TTYL, busy
ACCUMULATE ALL U CAN! OCTOBER IS OUR MONTH. Many with big ties to not only Pharma/Biotech, But Wealth Funds, Investing Firms Know of this Merger.
Just got to do your DD and Make Calls!! Catchers Mitt Is Out!! Lol!! Later
Catchers mitt is out for the impatient flipper. Later
Exactly. Just as The Gates Foundation does I am betting
DD! Start it off with Diskmans post today: Dr. Anthony Fauci talking about the effectiveness of Monoclonal Antibodies towards Covid-19 ..let’s get BioClonetics Immunotherapeutics funded
https://t.co/7WDBYA3VjQ?amp=1
The time to truly fight HIV and Covid is upon us with this Merger of Enzolytics Inc and BioClonetics. PATENTS, Sector Connections and Ties, TONS Of EXPERIENCE, on and on!
BioClonetics said that because of the similar structures of HIV and COVID-19 and the efficacy of its Clone 3 antibody in fighting HIV, the company has been asked by the National Science Foundation @NSF to submit a funding application for development of a COVID-19 antibody. The company currently has applications pending with the NSF and the National Institutes of Health.
Remember, this was months ago. Betting they got PLENTY TO TELL IN THE NEAR TERM.
our Duke PHD https://surgery.duke.edu/news/david-montefiori-phd-receives-326-million-grant-gates-foundation-hiv-vaccine-research
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158370680
LET THIS SINK IN: BioClonetics FINAL stage of development of a parent monoclonal antibody ("mAbs") (designated as Clone 3), which is non-toxic & has shown in initial in vitro testing 2 B Effective against More than 95% of ALL Strains & viral subtypes of HIV-1 against which it's been tested
BioClonetics INVITED by the National Science Foundation (NSF) 2 submit an application 4 funding 4 development of anti-SARS-Cov-2 monoclonal antibodies using its proprietary #Technology. Such application to the NSF & a corresponding application to the NIH R NOW PENDING
The Company is also looking to expand its Medical Advisory board with individuals that have direct experience taking medical products through the regulatory process and bringing them to market. Betting we do NOT have to look far for these Additions.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158391702
Okay, Now some serious ties: Easier to post pages so I do not run out of room, lmao!
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158402294
More on Genscript: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158402747
https://www.linkedin.com/in/craigvomlehn/ Click Interest, Then Companies!!!
ALSO http://bioclonetics.com/who-we-are.html
Key Figure is Tomasz Zastawny, Chief Clinical Operations Officer, DSc, Ph.D.
Vice President, Head of Clinical Operations at Epizyme
https://www.linkedin.com/company/epizyme/about/ HUGE!!!
$EPZY NASDAQ $13.26
Hello, my name is Rich Krebs. I'm currently a Senior Principal Scientist with Zoetis. We are an animal health company who recently introduced the first animal health monoclonal antibody treatment. I'm a believer in the concept and I believe your company is able to accomplish it's goals.
Richard Krebs
Senior Principal Scientist in R&D for an animal health company.
INVESTOR IN BioClonetics!!!
Look up Zoetis!!
Zoetis Inc. is the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. Wikipedia
Stock price: ZTS (NYSE) $160.87 +0.40 (+0.25%)
Sep 18, 4:05 PM EDT - Disclaimer THIS GUY INVESTED IN BIOCLONETICS FOLKS! U THINK THIS COMPANY KNOWS WHO BIOCLONETICS IS NOW??!!! LOL! I DO!
1 MORE BIGGIE DD and TIES.
THE BUZZ ABOUT BIOCLONETICS IMMUNOTHERAPEUTICS
Despite effective anti-HIV retrovirals, clearance of HIV-1 remains a critical global health issue. We are excited to be part of your strong interdisciplinary team and you have our full support for successful advancement of your technology.
Magdalena Leszczyniecka, Ph.D., MBA
CEO and Present, STC Biologics, Inc.
DD HER and Her Company!! Started at Novartis
Pharmaceuticals
https://stcbiologics.com/
STC was founded in 2009 and its team brings expertise in biologics drug development and global regulatory approvals from Genentech, Novartis, Shire, EMD Serono, Lonza, Alexion and Merrimack.
She gained start up experience prior to STC working for venture capital firms: Flagship Ventures and Atlas Ventures. She has led the development of MM-121 and anti-HER3 antibody programs at Merrimack Pharmaceuticals.
Here is more from her: https://www.rihl.in/hiv-curable-now-with-monoclonal-antibodies/
This is old, but once again, Shows People knowing People and Companies
Page 19 and 73
https://conshouston.esteri.it/resource/2011/11/42712_f_cons57RaccoltainterventiConferenzadeiRicercatori2010.pdf
Lastly, old but... you get the point!!
https://www.digitalnicheagency.com/ BUT...listed on the page with big names just looks nice as shit folks!!
CHEERS TO THIS MERGER!! GAMECHANGER!